ClinicalTrials.gg
WithdrawnNCT05622175DekaJointUpdated Dec 2, 2025

Safety and Preliminary Signs of Efficacy of F8IL10 for Intra-articular Treatment

A Phase 1 interventional study of F8IL10 in Rheumatoid Arthritis, sponsored by Philogen S.p.A.. Withdrawn. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2025-12-02.

Sponsored by Philogen S.p.A. · Phase 1, Interventional, and Treatment

Why this study was withdrawn
Study redesigned and registered under NCT07245992 (Protocol n° PH-F8IL10INTRA-03/24)

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
0
Allocation
Not applicable
Ages
18 Years to 80 Years
Sex
All
01

Study summary

This multicenter, prospective Phase I study is aimed at testing the safety of F8IL10 via i.a. administration once every 4 weeks over 8 weeks in patients with RA who, despite treatment with stable doses (at least 3 months) of DMARDs (conventional, biologic and/or targeted synthetic), present arthritis flare(s) suitable for i.a. injections.

02

Conditions studied

  • Rheumatoid Arthritis
03

In context

Arthritis, Rheumatoid

3,335 studies on the registry are indexed under Arthritis, Rheumatoid; 445 are open to participants now.

Browse Arthritis, Rheumatoid studies →

Lead sponsor

Philogen S.p.A. is the lead sponsor of 49 studies on the registry; 16 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Patients aged ≥18 and ≤ 80 years.
  2. Diagnosis of RA according to ACR/EULAR classification criteria (2010) with a disease duration exceeding 6 months.
  3. Presence of at least an arthritis flare suitable for i.a. injection despite treatment with stable doses (for at least 3 months) of DMARDs (conventional, biologic and targeted synthetic) background therapy.
  4. Stable regimens of NSAIDs and/or oral (≤ 10 mg/day; prednisone equivalent) for a period ≥ 2 weeks prior to screening.
  5. All acute toxic effects of any prior therapy must have returned to classification "mild" according to v.5.0 (published on November 27, 2017).
  6. Sufficient hematologic, liver and renal function:

    • (ANC) ≥ 1.5 x 109/L, ≥100 x109/L, (Hb) ≥ 10.0 g/dL.
    • Alkaline phosphatase (AP), (ALT) and or aspartate aminotransferase (AST) ≤ 3 x (ULN), and total ≤ 2.0 mg/dl (34.2 µmol/L).
    • Creatinine ≤ 1.5 ULN or 24 h ≥ 50 mL/min.
  7. Documented negative TB test (e.g. Quantiferon or equivalent) and Chest X-ray. Results of tests carried out prior to the participation in the study may be accepted, if deemed as appropriate to exclude active TB by the study physician.
  8. Documented negative test for --. For HBV serology, the determination of HBsAg and anti-HBcAg Ab is required. In patients with serology documenting previous exposure to HBV (i.e., anti-HBs Ab with no history of vaccination and/or anti-HBc Ab), negative serum HBV-DNA is required. For HCV, HCV-RNA or HCV antibody test is required. Subjects with a positive test for HCV antibody but no detection of HCV-RNA indicating no ongoing infection are eligible. Results of tests carried out prior to the participation in the study may be accepted, if deemed as appropriate to exclude active infections by the study physician.
  9. Sexually active male or female patients of are eligible providing that:

    Female:

    • Women of childbearing potential (WOCBP) have a negative pregnancy test performed within 14 days prior to treatment start.
    • WOCBP agree to use, from the screening to 6 months following the last study drug administration, effective method of as applicable per local law that both results in a Pearl index \< 1 and considered highly effective as defined by the "Recommendations for contraception and pregnancy testing in clinical trials" issued by the "Clinical Trial Facilitation Group" (e.g. combined estrogen and progestogen containing hormonal contraception, progestogen-only hormonal contraception, intrauterine device, intrauterine hormone-releasing system, vasectomized partner, total sexual abstinence or bilateral tubal occlusion).

    Male:

    - Agree to use two acceptable methods of contraception (e.g. condom with spermicidal gel) from the screening to 6 months following the last study drug administration. Females of childbearing potential that are partners of male study participants must observe the same birth control indications that apply to female participants.

  10. Signed and dated Ethics Committee-approved form indicating that the patient has been informed of all pertinent aspects of the study.
  11. Willingness and ability to comply with the scheduled visits, treatment plan, laboratory tests and other study procedures.

Exclusion criteria

Exclusion Criteria:

Patients must not be enrolled into the study if, at the time of enrollment, they have any of the following:

  1. Presence of active infections or other severe concurrent disease, which, in the opinion of the investigator, would place the patient at undue risk or would interfere with the study objectives or conduct.
  2. Pregnancy, lactation or unwillingness to use adequate methods.
  3. Diagnosis of any other inflammatory arthritis or active diseases other than RA.
  4. Received intra-articular administration of /DMARDs (for other reasons than the current study) within 4 weeks or 5 half-lives prior to the first dose of study drug, whichever is longer.
  5. History or currently active primary or secondary immunodeficiency.
  6. Concurrent or history of malignancy (except in situ melanoma) from which the patient has been disease-free for less than 2 years.
  7. History within the last year of acute or subacute coronary syndromes including myocardial infarction, unstable or severe stable angina pectoris.
  8. Treatment with warfarin or other coumarin derivatives.
  9. cardiac arrhythmias or requiring permanent medication.
  10. Abnormal or any other abnormalities observed during baseline and echocardiogram investigations that are considered as clinically significant by the investigator; subjects with current or a history of /QTc prolongation.
  11. Uncontrolled hypertension.
  12. Known arterial aneurism at high risk of rupture.
  13. Ischemic peripheral vascular disease (Grade IIb-IV according to Leriche-Fontaine classification).
  14. Severe diabetic retinopathy.
  15. Major trauma including surgery within 4 weeks prior to administration of study treatment.
  16. Known history of allergy or other intolerance to IL10 or other drugs based on human proteins/peptides/antibodies.
  17. Treatment with any agent within 4 weeks or 5 half-lives prior to the first dose of study drug, whichever is longer.
  18. Immunization with a live/attenuated vaccine within 4 weeks prior to baseline or plan to receive vaccines during the study.
  19. Chronic pain disorders (not RA-related) that might interfere with pain evaluation.
  20. Patients requiring stable doses of corticosteroids > 10 mg/day (prednisone equivalent). Limited use of corticosteroids to treat or prevent acute reactions is not considered an exclusion criterion.
  21. History of alcohol, drug or chemical substance abuse within the 6 months prior to screening.
  22. Any condition that in the opinion of the investigator could hamper compliance with the study protocol.
Terms in these criteria, in plain language(23)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
0 participants (actual)

Study arms

  • Experimental
    Drug: F8IL10

    Overall, 32 patients will participate in case no DLT would occur. 1. In the standard 3+3 dose escalation part, participants will be enrolled in cohorts and will be treated with different doses of F8IL10 (from 0.5 to 10 mg) in order to identify a RD to be further explored in the subsequent dose expansion part. In the dose escalation part, patients will be treated in cohorts of 3 patients with escalating doses of F8IL10 until the MAD is reached and won't exceed 10 mg dose level. In case a DLT would be detected, further 3 patients will be enrolled for that cohort in order to confirm the MAD or to proceed with the next dose level. Therefore, up to 30 patients could be enrolled in the dose escalation part. 2. Following successful identification of the RD, the study will proceed with a dose expansion part and 20 patients will be treated at the RD dose level (patients treated at the RD in the course of the dose escalation phase will contribute to the total sample size).

    Drug: F8IL10

Interventions

  • DrugF8IL10

    The study consists of a dose escalation of F8IL10 to determine the MTD and the RD when administered intra-articular. Patients with arthritis flare(s) in "large joints" (shoulders, elbows, knees and ankles, with the exception of hip) and "small joints" (metacarpophalangeal joints, proximal interphalangeal joints, second through fifth metatarsal-phalangeal joints, thumb interphalangeal joints, and wrists) defined as per "2010 Rheumatoid Arthritis Classification Criteria" \[1\] will be treated with increasing dose of F8IL10 according to the schedule detailed below: Cohort 1: 0.5 mg F8IL10 Cohort 2: 1 mg F8IL10 Cohort 3: 2.5 mg F8IL10 Cohort 4: 5 mg F8IL10 Cohort 5: 10 mg F8IL10

    Also known as: Dekavil

06

What researchers measure

Primary outcomes

  1. MTD

    Maximum Tolerated Dose (in dose escalation part). The MAD is defined when at least two patients within a cohort of 2-6 patients experience a DLT (i.e., ≥33% of patients with a DLT at that dose level.

    Time frame: From the enrollment of each patient until the completion of the treatment (for a maximum of 9 weeks)

  2. RD

    Recommended Dose (in dose escalation part). The RD is defined by the Data Safety Monitoring Board (DSMB) among the safely tested dose level (i.e. not exceeding the MTD) considering the overall results dataset (e.g. safety, tolerability, efficacy, immunogenicity, pharmacokinetics) obtained in this study.

    Time frame: From the enrollment of each patient until the completion of the treatment (for a maximum of 9 weeks)

Secondary outcomes

  1. Safety and Tolerability

    Number and frequency of Adverse Events (AEs), Serious Adverse Events (SAEs), Dose Limiting Toxicities (DLTs) and Drug-Induced Liver Injuries (DILIs)

    Time frame: From the start of treatment period (for a maximum of 9 weeks) to the end of follow-up period (for a maximum of 6 months)

  2. Efficacy measured as improvement in visual analogue scale for involved joint pain (jVAS)

    Preliminary efficay findings using jVAS scale in rheumatoid arthritis for quantifying pain intensity. Patients will assess their own current level of pain related to arthritis in target joint(s) that has been/will be injected. The information refers to a score of the joint pain perceived by the patient over the 7 days prior to the assessment and will be recorded using a 100-mm horizontal VAS where the left end represents "no pain (0%)" and the right end represents "severe pain (100%)". The assessment provided at Day 1 (Week 1) will be considered as baseline measurement.

    Time frame: From the start of treatment period (for a maximum of 9 weeks) to the end of follow-up period (for a maximum of 6 months)

  3. Quality of life - Collection of HAQ-DI for the evaluation of physical function

    Health Assessment Questionnaire-Disability Index (HAQ-DI) as validated tool for the evaluation of Disability Index (DI) or Functional Disability Index (FDI) by considering 8 sections: dressing, arising, eating, walking, hygiene, reach, grip, and activities. There are 2 or 3 questions for each section. Scoring within each section is from 0 (without any difficulty) to 3 (unable to do). For each section, the score given to that section is the worst score within the section. The 8 scores of the 8 sections are summed and divided by 8. Changes from baseline through treatment period and follow-up will be quantified.

    Time frame: At day 1 and 29 (F8IL10 administration) to the end of follow-up period (for a maximum of 6 months)

  4. Quality of life - Collection of SF-36 for the evaluation of overall health status

    Short Form Health Survey 36 (SF-36) as validated tool for subject-reported indication of overall health status, including multi-item scales measuring 8 health concepts: (1) physical functioning; (2) role limitations because of physical health problems; (3) bodily pain; (4) social functioning; (5) general mental health; (6) role limitations because of emotional problems; (7) vitality; and (8) general health perceptions. These are summarized in two summary measures of physical and mental health: the Physical Component Summary and Mental Component Summary. Lower scores equate to higher disability and higher scores equate to lower disability. Changes from baseline through treatment period and follow-up will be quantified.

    Time frame: At day 1 and 29 (F8IL10 administration) to the end of follow-up period (for a maximum of 6 months)

  5. Quality of life - Collection of FACIT-F for the evaluation of self-reported fatigue and its impact upon daily activities and function

    Functional Assessment of Chronic Illness Therapy - Fatigue (FACIT-F) as validated 13-item questionnaire for the assessment of self-reported fatigue and its impact upon daily activities and function. It uses a 5-point Likert-type scale (0 = not at all; 1 = a little bit; 2 = somewhat; 3 = quite a bit; 4 = very much). As each of the 13 items of the FACIT-Fatigue scale ranges from 0-4, the range of possible scores is 0-52, with 0 being the worst possible score and 52 the best. Changes from baseline through treatment period and follow-up will be quantified.

    Time frame: At day 1 and 29 (F8IL10 administration) to the end of follow-up period (for a maximum of 6 months)

  6. Assessment of joint inflammation with ultrasound

    Assessment of improvement of joint synovitis using ultrasound (US) pre-treatment and after the treatment period

    Time frame: At day 1 and 57 of treatment period

  7. Assessment of damage with ultrasound

    Assessment of non-progressive bone erosion using ultrasound (US) pre-treatment and after the treatment period

    Time frame: At day 1 and 57 of treatment period

  8. Pharmacokinetic (PK) profile F8IL10- Area Under the Curve (AUC)

    Blood/Synovial fluid samples for PK profile of F8IL10 profile measurements will be collected from all patients enrolled in the study and who receives at least one dose of study drug and have adequate PK sampling. Standard PK parameter AUC will be estimated.

    Time frame: At day 1 and 29 (F8IL10 administration)

  9. Pharmacokinetic (PK) profile F8IL10- Maximum drug concentration (Cmax)

    Blood/Synovial fluid samples for PK profile of F8IL10 profile measurements will be collected from all patients enrolled in the study and who receives at least one dose of study drug and have adequate PK sampling. Standard PK parameter Cmax will be estimated.

    Time frame: At day 1 and 29 (F8IL10 administration)

  10. Pharmacokinetic (PK) profile F8IL10 - Terminal half-life (T½)

    Blood/Synovial fluid samples for PK profile of F8IL10 profile measurements will be collected from all patients enrolled in the study and who receives at least one dose of study drug and have adequate PK sampling. Standard PK parameter T½ will be estimated.

    Time frame: At day 1 and 29 (F8IL10 administration)

  11. Immunogenicity of F8IL10 (Human Anti-Fusion Antibody formation [HAFA])

    Blood samples to assess the potential development of antibody formation to F8IL10 will be collected during the treatment period and in the first Follow-up

    Time frame: At day 1 and 29 (F8IL10 administration) to the first visit of follow up (week 13)

07

Study locations

No study locations are listed for this record.

08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Mar 2023; primary completion for Dec 2025, 33 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 3, 2022
First posted
Nov 18, 2022
StartEst.
Mar 31, 2023
Primary completionEst.
Dec 31, 2025
CompletionEst.
Dec 31, 2026
Last update
Dec 2, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 2, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05622175
Lead sponsor
Philogen S.p.A.
Responsible party
Sponsor
First posted
Nov 18, 2022
Start date
Mar 31, 2023 (estimated)
Primary completion
Dec 31, 2025 (estimated)
Completion
Dec 31, 2026 (estimated)
Last update
Dec 2, 2025

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is withdrawn, as verified in Nov 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion